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ABSTRACT 
Background: Ekberg’s criteria for liver resections (LR) of colorectal cancer liver metastases (CRCLM) have 
been accepted as a “dogma” and the procedure – as a “gold standard” since 1986. There are many well-
known predictive factors for the early and long-term results in this field of surgery. However, some of them 
are still a matter of debate. 
Aim: Study on the possible prognostic value of some clinical-pathological factors for the early and late re-
sults after major LR (≥ 2 segments) of CRCLM. 
Material and methods: A total of 143 radical (R0) major LR (≥ 2 segments) of synchronous and metachro-
nous CRCLM were performed between 01.01.20007 – 31.12.2014 in the Clinic of Liver, Biliary, Pancreat-
ic and General Surgery, Tokuda Hospital Sofia. The design of the study was “a single center” and “retro-
spective”. We analyzed the data with possible predictive value - demography, comorbidity, liver function, 
АSA group, neoadjuvant chemotherapy, type and characteristics of the surgical procedure, pathological 
data (T,N,G,H) and time of detection of metastases (synchronous or metachronous). The early postopera-
tive morbidity and mortality rates were compared with these factors looking for correlation. The long-term 
follow-up period was ≥ 12 months for 86 patients (60.1%). 
Results: The early postoperative mortality rate was 2.8% (4 cases) for the whole series. The specific morbid-
ity rates were significantly higher in patients above 65 years of age, with ≥ 3 comorbid conditions, multi-
visceral resections in cases of synchronous metastases and atypical (non-anatomical) LR. The majority of 
CRCLM cases were ≥ Т2, N (+) positive and G2-3. Unfavorable prognostic factors were the detection of meta-
chronous lesions earlier than 12 months after a curative previous resection especially on the basis of ade-
quate chemotherapy. 
Conclusions: The knowledge on prognostic factors in patients with CRCLM as well as on indications and 
contraindications helps the correct preoperative judgment on choosing the right and appropriate type and 
volume of surgical procedures. 
Keywords: colorectal cancer (CRC); colorectal cancer liver metastases (CRCLM); liver resection (LR); ma-
jor liver resection (MLR) specific post-resection complications (SPRC)
BACKGROUND 
Ekberg’s criteria for liver resections (LR) 
of colorectal cancer liver metastases (CRCLM) 
have been accepted as a “dogma” and the 
procedure itself - as a “golden standard” since 
1986 [11]. The good long-term results are the 
logical consequence not only of the progress 
in LR surgery but also of the invention and 
К. Draganov, А. Petreska, D. Rusenov et al.
Scripta Scientifica Medica, vol. 47, Supplement 1, 2015, pp. 42-47
Copyright © Medical University of Varna   43
usage of highly effective chemotherapeutic 
drugs for CRC [2,5,6,8,9,11,13,15]. There are 
many well studied predictive factors for the 
early postoperative results, disease free survival 
(DFS) and overall survival (OS) after resection 
procedures of CRCLM. However some of them 
are still a matter of debate. In this course of 
issues it is very important for a surgeon to have 
profound knowledge in the next three aspects: (а) 
judgment of the resectability in every particular 
case of CRCLM based on the main principles 
of oncology; (b) avoiding major liver resection 
(MLR), i.e. „senseless surgical aggression” 
when there are high perioperative risks for 
specific post-resection complications (SPRC); 
(c) defining the right multimodal approach – 
time appointment of methods, one- or two-
stage surgery, liver metastases or primary tumor 
removal as the first? 
AIM
To study the possible prognostic value of 
some clinic-pathological factors for the early and 
late results after MLR (≥ 2 segments) of CRCLM. 
MATERIAL AND METHODS
A total of 143 radical (R0) MLR (≥ 2 
segments) of synchronous and metachronous 
CRCLM were performed between January, 1 
2007 – December, 31 2014 in the Clinic of Liver, 
Biliary, Pancreatic and General Surgery, Tokuda 
Hospital Sofia. The design of the study was “a 
single center” and “retrospective”. Patients with 
excision biopsy in multiple residual metastases 
as well as patients with very small enucleations 
and/or wedge resections were excluded because 
of very low risk for SPRC. Patients were divided 
in two groups according to the volume of 
the procedure – only LR or LR as a part of a 
multiple organ resection. Group 1 included 110 
cases (76,9%) with a LR alone which had been 
performed in two situations: (1) metachronous 
CRCLM after a previous curative (radical) 
resection of the large intestine; (2) synchronous 
CRCLM judged as indicated for a two-step 
procedure – primary tumor removal as the first 
step and LR after that. Group 2 consisted of all 
the rest 33 patients (23.1%) with synchronous 
CRCLM who received a one-step procedure – 
primary tumor removal plus LR. 
We analyzed 2 categories of factors. 
The first category included factors with a 
possible predictive value for the early results – 
demography, comorbidity, liver function, АSA 
group, neoadjuvant chemotherapy, type and 
characteristics of the surgical procedure (LR 
alone or as a part of a multiple organ resection); 
anatomical or atypical (non-anatomical) LR. 
Chemotherapy again, pathological characteristics 
(T,N,G,H) and the time of detection of metastases 
(synchronous or metachronous) were included in 
the second category, which was of quite possible 
predictive value for the remote results. The early 
postoperative morbidity and mortality rates 
were compared with the first category of factors 
looking for correlation. The long-term follow-up 
period was ≥ 12 months for 86 patients (60.1%). 
So the DFS and OS data were compared to the 
second category of factors. 
RESULTS
The mean age in both groups was 63.7 
years (range 40-82 years) with a prevalence of 
those under 65 years of age - 82 cases (57.3%) 
and 51 cases (42,7%) were > 65 years of age. LR 
of CRCLM as one- or two-stage procedure was 
performed as an exception in patients above 70 
years of age, who were only 2.8% from all cases 
(4 patients). The male/female ratio was 1.7/1 (91 
men/52 women).
The comorbidity data were an interesting 
issue because of the age structure of our groups. 
Comorbid conditions were registered in 108 
patients (75.5%). Cardio-vascular disorders 
(high blood pressure and ischemic heart disease), 
anemia and diabetes were the most common 
ones. Pulmonary (chronic obstructive bronchitis 
and asthma) and other diseases were diagnosed 
much more rarely. There was no patient with 5 
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concomitant diseases and only 13 of them (9.1%) 
had 4 comorbidities. 
Biochemical blood tests found unimportant 
deviations in blood glucose, serum albumin, 
cholestatic and cytolytic enzymes and 
coagulation. We routinely performed pre-
resection preparation with hepatoprotective 
agents, correction and substitution. Obligatory 
conditions before performing MLR of 
synchronous or metachronous CRCLM were 
Hb>100 g/L, total bilirubin<21 µmol/l, ASAT 
and ALAT <80 UI/l, INR<1,35 and АРТТ<35 
sec. All the 143 patients from our study were 
ASA group ≤ 3. 
The mean time of detection of metachronous 
CRCLM was 11.7 months (range 5-46 months) 
after previous curative large intestine resection.
Anatomical MLR accounted for 54.5% of 
all surgeries, predominantly in group 1 - 64.5% 
of all procedures. The synchronous metastases 
were mainly removed atypically (Table. 1). 
The mean procedure duration was 3.68 
hours (3-7 hours) in group 1 and 4.58 hours (3-8 
hours) in group 2 (p<0.05). Approximately half 
of the patients needed blood transfusion - 51/110 
(46.4%) and 17/33 (51.5%) from group 1 and 
group 2 respectively. Substitution with ≥ 2 RBC 
packages was necessary in only 16 cases (11.2%). 
Pathological diagnosis and staging was 
possible in 125 cases because the remaining 18 
patients from group 1 had received the previous 
procedure in other hospitals and the T,N,G-
data were insufficient. Most cases were Т2-3 
(80,4%), N(+) positive (90,4%) and G2,3 (64,0%) 
demonstrated on table 2. Twelve biopsies had 
a negative N-status which is not casuistic 
according to our experience and according 
to literature data. However we didn’t find 
prevalence of locally advanced cancer, i.e. T4 in 
metastatic diseases.
The early postoperative mortality rate was 
2.8% (4 cases) for the whole series - 2/110 (1.8%) 
in group 1 and 2/33 (6.06%) in group 2. The fatal 
outcome was caused by acute liver failure (2 
cases), sepsis with MODS and MOF (1 case) and 
pulmonary embolism (1 case).
The specific morbidity rate (table.3) was 
significantly higher in group 2 affecting 13/33 
patients (39.4%) while in group 1 only 36/110 
(32.7%). Conservative treatment succeeded in 
29 of the   complicated cases and the number 
of interventional procedures was 14, presented 
by US guided drainage of perihepatic f luid 
collections, ERCP + stent in the common bile 
duct, management of abdominal drainages in 
cases of pathologic secretion, pleural drainage 
in cases of effusions, etc. Reoperations received 
6 patients (4,2% from the whole serie). None of 
the reoperated patients had a fatal outcome.
An analysis and comparison of data showed 
that SPRC were more common in patients above 
65 years of age, with ≥ 3 comorbid conditions, 
after multivisceral resections of synchronous 
liver metastases (group 2) and after atypical 
(non-anatomical) MLR. The procedure duration 
and the blood transfusion didn’t have any 
prognostic value. In this item an explanation is 
a must: only 11.2% of the operated patients were 
substituted with ≥ 2 RBC units.   
Eighty six cases (60.1%) were followed up 
for a period of more than 12 months. Recurrent 
liver metastatic disease was diagnosed in 52 of 
them (60.5% of the followed up) and extrahepatic 
involvement (lungs, bones) affected 6 patients 
(7.0%). An early recurrence (< 6 months after 
a previous radical procedure) was detected in 
21 patients (24.4%). Significantly unfavorable 
prognostic factors were the synchronous 
liver lesions or the metachronous ones which 
appeared ≤ 8 months after a previous radical 
intestinal resection on the bases of adequate 
chemotherapy.”T”,”N” and “G” categories did 
not demonstrate correlation to the recurrence 
rates in our material.
DISCUSSION
A surgical resection is the main treatment 
option for patients with CRCLM that leads to 
a mean survival period of 24-42 months and 
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Table. 1. Anatomical vs atypical LR of metachronous (group1) and synchronous (group 2) CRCLM
Characteristics of liver resection (LR) 
Metastases type – resection type 
Group 1 
LR only  
Group 2 
liver + intestinal resection Total 
 Anatomical Number 71 7 78 
% in the group 64,5% 21,2% 54,5%
Atypical Number 39 26 65 
% in the group 35,5% 78,8% 45,5%
Total Number 110 33 143
% from all 76,9% 23,1% 100%
% total 100% 100% 100%
Table. 2. T, N и G-categories in patients with CRCLM





















Table. 3. Specific post-resection complications after resection of metachronous (group 1) and synchronous (group2) 
CRCLM
* Code for the „type of complication“:  0 – no SPRC registered;  1 – SPRC, treated conservatively;  2 – SPCR, treated by an 
interventional procedure (percutaneous drainage under US guide; pig-tail catheter; drainage of a pleural effusion); 3 – 
SPRC necessitating reoperation
Complications – code* Group 1 Group 2  
Code 0  74 (67,3%) 20 (60,6%) 
Code 1  19 (17,3%) 10 (30,3%) 
Code 2 12 (10,9%) 2 (6,1%) 
Code 3  5 (4,5%) 1 (3,0%) 
Total 110 (100.0%) 33 (100.0%) 
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a 3- and 5-year survival rates of 50% and 35% 
respectively [8,9].  Chemotherapy alone can reach 
less than 10% 5-year survival [7]. A considerable 
contribution to the improvement of long-term 
results (DFS, OS) was given by the progress in 
drug development [1,3,4,13]. The introduction 
of monoclonal antibodies against vascular 
endothelial growth factor (bevacizumab = VEGF 
antibodies) in last decade amended significantly 
the local cancer control and slowed down the 
progression and metastasizing [12,15]. 
The main issues before undertaking 
resection of CRCLM are the following six ones: (1) 
What’s the general condition of the patient, i.e. is 
he/she able to stand and survive a major surgery; 
(2) Is there a possibility for R0-resection; (3) Will 
be there sufficient residual liver parenchyma or 
the so- called ”future liver remnant” (FLR); (4) 
Is there a possibility for preserving at least two 
liver segments with adequate blood in-flow and 
out-flow as well as adequate biliary drainage; 
(5) What are the biological characteristics of 
the tumor itself (is it more or less aggressive) 
which justifies aggressive surgical approach with 
expected long-term benefit; (6) Is the surgical 
team experienced enough [11]. 
A very important corner-stone is the FLR 
specificity [2]. A FLR must be ≥ 25% of the pre-
surgery volume in patients with „healthy liver”, 
≥ 40 % in cases of steatosis, fibrosis, concomitant 
diabetes and after aggressive chemotherapy and 
> 50% in cirrhotics [11].
About 30% of patients with synchronous/
metachronous CRCLM have only hepatic 
involvement at the time of establishing the 
diagnosis [16]. Less than 25% of these 30% are 
candidates for LR since the rest of cases present 
with bilobar multiple lesions (Н3) and/or major 
blood vessels infiltration and/or impossibility 
for R0 procedure which would preserve at least 
two anatomical segments [6]. Neoadjuvant 
chemotherapy leads to down-sizing and down-
staging in 15-30% of unresectable cases making 
them resectable. In our series there are no such 
data because the great majority of unresectable 
cases get their consultations as out-patients 
without admitting to hospital. At the same 
time many ”unresectable” patients who have 
received chemotherapy seek a consultation at 
another surgeon with the hope to be promised 
an  operation.
„Early recurrence” is one of the main 
problems affecting patients who have undergone 
LR of CRCLM. In 2014 R.Adam et al. reported 
their series including 6025 CRCLM patients 
who had received radical procedures since 1998 
till 2009 [5]. Recurrence was diagnosed in 2734 
cases (45.4%) and 639 of them (10.6%) were 
early recurrences, i.e. less than 6 months after 
a previous LR. Т3-4, synchromous LM, „simple 
metastasectomy” (resection margin of 0 mm!) 
and intraoperative radio frequency thermo-
ablation were proven as risk factors for early 
recurrence while the response to chemotherapy 
could significantly reduce that risk. The 5-year 
survival rate of early recurrent cases was 26.9% 
while of late recurrent cases it reached 49.4%. 
We diagnosed 24.4% early recurrences 
among the 86 followed-up cases in our series. 
A profound analysis of the operative protocols 
and other medical reports concerning pathology 
staging and chemotherapy demonstrated the 
importance of advanced T as a risk factor for 
early recurrence. But no cases of resection 
margin < 1.0 cm were found in the files so it was 
impossible for us to estimate it as a risk factor.       
CONCLUSIONS
The knowledge on prognostic factors for 
early and late postoperative results in patients 
with MLR of CRCLM (as a single procedure or 
as a part of multimodal treatment) helps the 
correct preoperative judgment on: (1) the type 
and volume of the planned procedure; (2) the 
risk of specific post-resection complication; 
(3) the expected long-term results. Thus the 
oncologic basis of surgery is respected.
Risk factors for SPRC include patient’s age 
above 65 years, the presence of more than 3 
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comorbid conditions, a multivisceral resection 
and a non-anatomical (atypical) LR. 
Unfortunately, we registered high 
absolute number (52) and relative share 
(60.5%) of recurrent liver metastases in our 
series. Significant prognostic factors were 
synchronous metastases and the development of 
metachronous lesions less than 8 months after a 
previous curative intestinal resection especially 
in the background of chemotherapy. 
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